8-K: HCW Biologics Reports Q3 2025 Results, Advances Clinical Programs

HCW Biologics Inc. announced its third quarter 2025 financial results and provided updates on its clinical development programs, including the anticipated dosing of the first patient in a Phase 1 study for HCW9302.

Summary

• Reported Q3 2025 financial results and business highlights.
• Anticipates dosing the first patient in a Phase 1 clinical study (NCT07049328) for HCW9302 in patients with an autoimmune disease in Q4 2025.
• HCW9302 is the lead product candidate for autoimmune diseases and inflammatory conditions, a subcutaneously injectable IL-2 fusion molecule.
• Launched a search for a commercial partner for its T-cell engager (TCE) compounds.
• Issued 475,000 shares of Common Stock for gross proceeds of $2.2 million in Q3 2025 via a Standby Equity Purchase Agreement.
• Successfully opened two clinical sites for the HCW9302 Phase 1 trial in alopecia areata, expecting first patient dosing in Q4 2025.
• Showcased data for lead engager HCW11-018b and second-generation immune checkpoint inhibitor HCW11-040 at SITC.
• Revenues for Q3 2025 were $15,606, down from $426,423 in Q3 2024.
• Net loss for Q3 2025 was $4.6 million, compared to $3.9 million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, was $8.7 million, significantly lower than $26.7 million for the same period in 2024.
• Substantial doubt exists regarding the ability to continue as a going concern for at least 12 months without additional funding.
• Nasdaq Hearings Panel granted continued listing subject to compliance with the $2.5 million stockholders' equity rule by December 31, 2025.

Sentiment

Score: 4

Explanation: While there are positive clinical development updates and a significant reduction in the nine-month net loss, the severe decline in revenue, increased quarterly net loss, explicit 'going concern' warning, and Nasdaq listing deficiency create significant financial uncertainty and overshadow the clinical progress. The need for substantial additional funding and the outstanding legal fees are major concerns.

Positives

• Anticipates dosing the first patient in a Phase 1 clinical study for HCW9302 in autoimmune disease in Q4 2025.
• Successfully opened two clinical sites and is actively screening patients for the HCW9302 Phase 1 trial in alopecia areata.
• Showcased promising preclinical data for lead engager HCW11-018b and second-generation immune checkpoint inhibitor HCW11-040 at SITC.
• Net loss for the nine months ended September 30, 2025, decreased significantly to $8.7 million from $26.7 million in the same period of 2024, primarily due to a $1.6 million legal expense recovery and lower R&D expenses.
• Received a $2.0 million insurance reimbursement in January 2025 related to legal fees.
• Nasdaq Hearings Panel granted continued listing, providing an extension to meet the $2.5 million stockholders' equity requirement by December 31, 2025.
• HCW9302 is a first-in-kind IL-2 fusion molecule targeting Treg cells, a mechanism recently acknowledged by the 2025 Nobel Prize in Physiology or Medicine.
• Launched a search for a strong commercial partner for its T-cell engager (TCE) compounds, indicating potential future collaborations and funding.

Negatives

• Revenues for the three months ended September 30, 2025, decreased significantly to $15,606 from $426,423 in the same period of 2024.
• Revenues for the nine months ended September 30, 2025, decreased significantly to $27,222 from $2.2 million in the same period of 2024, due to a one-year suspension of the Wugen License Agreement.
• Net loss for the three months ended September 30, 2025, increased to $4.6 million from $3.9 million in the same period of 2024.
• General and administrative (G&A) expenses increased by 15% for Q3 2025 and 29% for the nine months ended September 30, 2025, primarily due to salaries, benefits, and professional fees.
• Substantial doubt exists regarding the ability to continue as a going concern for at least 12 months from the issuance date of the audited financial statements without additional funding.
• Currently deficient in meeting Nasdaq Listing Rule 5550(b)(1) related to maintaining a $2.5 million balance in stockholders' equity.
• $12.1 million in legal fees remain unpaid, and the company is engaged in discussions for a payment plan.
• Cash and cash equivalents decreased from $4.67 million at December 31, 2024, to $1.10 million at September 30, 2025.

Risks

• Substantial doubt exists regarding the ability to continue as a going concern for at least 12 months without additional funding or financial support.
• Cannot be assured of continued success with remaining elements of the multi-step financing plan.
• Compliance with Nasdaq Listing Rule 5550(b)(1) (Equity Rule) requiring a $2.5 million balance in stockholders' equity is deficient, with a deadline of December 31, 2025.
• Future capital-raising plans and ability to continue with clinical development efforts are uncertain.
• Ability to pay $12.1 million in unpaid legal fees incurred in connection with the arbitration with ImmunityBio and its affiliates.
• Inherent uncertainties, risks, and assumptions associated with forward-looking statements, including the ability to develop new immunotherapeutic treatments, timing of study initiations, cash runway, and success of product candidates.

Future Outlook

The company anticipates dosing the first patient in a Phase 1 clinical study for HCW9302 in an autoimmune disease in the fourth quarter of 2025. Management hopes to rapidly expand clinical development of HCW9302 into Phase 2 studies for alopecia areata and other autoimmune/inflammatory conditions after establishing a safe and effective dose. The company is also seeking a commercial partner for its T-cell engager compounds and is undergoing IND-enabling studies for three TRBC-based molecules for cancer and age-related diseases. However, substantial doubt exists regarding the company's ability to continue as a going concern without additional funding, and it must comply with Nasdaq's $2.5 million stockholders' equity rule by December 31, 2025.

Management Comments

• "The goal of our Phase 1 clinical study for HCW9302 is to establish the safe dose that effectively increases Treg cell activity in patients with an autoimmune disease."
• "Once we achieve this objective, we hope to rapidly expand clinical development of HCW9302 in Phase 2 studies in patients with alopecia areata as well as other autoimmune diseases and inflammatory conditions."

Industry Context

HCW Biologics operates in the highly competitive clinical-stage biopharmaceutical sector, focusing on immunotherapies for chronic inflammation, autoimmune diseases, and cancer. The company's lead candidate, HCW9302, leverages IL-2 to modulate Treg cells, a mechanism recently highlighted by the 2025 Nobel Prize in Physiology or Medicine, underscoring the scientific relevance and potential of its approach. Its second-generation T-cell engager and immune checkpoint inhibitor programs aim to address limitations of existing therapies, positioning the company within a rapidly evolving oncology and immunology landscape where innovation in targeting tumor microenvironments and T-cell exhaustion is critical. The pursuit of commercial partners for its TCE compounds aligns with industry trends of strategic collaborations to de-risk and accelerate drug development.

Comparison to Industry Standards

• The company's focus on Treg cell modulation with HCW9302 is aligned with cutting-edge immunology research, as evidenced by the 2025 Nobel Prize for Treg cell discovery. This positions HCW Biologics at the forefront of a promising therapeutic area, similar to how companies like Amgen (with IL-2 therapies) or Roche (with autoimmune treatments) have explored immune modulation.
• The development of second-generation T-cell engagers (TCEs) like HCW11-018b aims to overcome limitations of first-generation products, a common industry challenge. Companies like Amgen (with Blincyto) and Regeneron (with bispecific antibodies) are also developing advanced TCEs, suggesting HCW Biologics is competing in a high-innovation space.
• The immune checkpoint inhibitor program, featuring HCW11-040 (a TRBC-pembrolizumab-based compound), seeks to improve upon existing therapies like Merck's Keytruda (pembrolizumab) by expanding TPEX cells without inducing cytokine storms, a significant safety and efficacy hurdle in the field.
• The company's financial position, particularly the "going concern" doubt and Nasdaq equity deficiency, contrasts sharply with established industry players who typically have robust cash reserves or clear funding pathways for clinical development. This indicates a higher financial risk profile compared to well-capitalized peers.

Legal Proceedings

• Legal fees incurred for an Arbitration which held its hearing in May 2024, was settled on July 13, 2024, and dismissed on December 24, 2024.
• Received a $2.0 million insurance reimbursement in January 2025 related to the Arbitration.
• Engaged in discussions with law firms to arrange a reasonable payment plan for $12.1 million in legal fees which remain unpaid.

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises, risk of delisting from Nasdaq if equity requirements are not met, uncertainty regarding the company's ability to continue as a going concern, but also potential upside from clinical trial advancements.
• Employees: Continued employment depends on the company's ability to secure additional funding and maintain operations.
• Customers/Patients: Potential for new therapeutic options if clinical trials are successful, particularly for autoimmune diseases like alopecia areata and various cancers.
• Creditors: Risk associated with $12.1 million in unpaid legal fees and the company's going concern status.

Next Steps

• Dose the first patient in a Phase 1 clinical study (NCT07049328) for HCW9302 in patients with an autoimmune disease in Q4 2025.
• Expand clinical development of HCW9302 into Phase 2 studies for alopecia areata and other autoimmune/inflammatory conditions after establishing a safe dose.
• Continue the search for a strong commercial partner for T-cell engager (TCE) compounds.
• Continue IND-enabling studies for three TRBC-based molecules for cancer and age-related diseases.
• Comply with Nasdaq Listing Rule 5550(b)(1) by maintaining a $2.5 million balance in stockholders' equity by December 31, 2025.
• Engage in discussions with law firms to arrange a reasonable payment plan for $12.1 million in unpaid legal fees.
• Implement remaining elements of the multi-step financing plan to secure additional funding.

Key Dates

Recommendation

Despite promising clinical advancements and a significant reduction in the nine-month net loss, the company faces severe financial distress. The explicit 'substantial doubt' about its ability to continue as a going concern, the significant decline in revenue due to a suspended licensing agreement, and the ongoing Nasdaq listing deficiency due to insufficient stockholders' equity present critical red flags. The need for substantial additional funding and the outstanding $12.1 million in legal fees create an immediate and high-risk financial environment. While clinical progress is positive, the financial instability and uncertainty outweigh these developments, making the stock a high-risk 'sell' for investors until a clear and sustainable funding pathway is established and Nasdaq compliance is secured.

Keywords

HCW Biologics, HCWB, Biopharmaceutical, Immunotherapy, Autoimmune Disease, Alopecia Areata, HCW9302, Clinical Trial, Phase 1, Treg cells, IL-2, T-cell Engager, Oncology, Inflammation, Nasdaq Listing, Going Concern, Financial Results, Q3 2025, Drug Development